Development of Tazobactam/Piperacillin Optimal Individualized Dose and Route for Maximize the Effects in Empiric Therapy.

Development of Tazobactam/Piperacillin Optimal Individualized Dose and Route for Maximize the Effects in Empiric Therapy. - Development of Tazobactam/Piperacillin Optimal Individualized Dose and Route for Maximize the Effects in Empiric Therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050335

Enrollment

Registered

2023-02-14

Start date

2023-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

One or more of the following infections: sepsis, pneumonia, peritonitis, intra-abdominal abscess, cholecystitis, and cholangitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have provided written informed consent of their own free will

Exclusion criteria

Exclusion criteria: Patients on dialysis Patients scheduled for less than 3 days of treatment with Tazobactam/Piperacillin Other patients deemed inappropriate by the attending physician

Design outcomes

Primary

Measure	Time frame
Measure blood levels by blood draw 3-5 days after starting tazobactam/piperacillin. Blood sampling points are 3 points: trough concentration, concentrations 1 and 2 hours after the end of infusion. (5mL each)	—

Countries

Japan

Contacts

Public ContactYoshitaka Kawaguchi

Yamaguchi University Hospital Department of Pharmacy

y.kawa@yamaguchi-u.ac.jp0836-22-2669

Outcome results